Neurodevelopmental Outcomes at Age 5 Years After Prophylactic Early High-Dose Recombinant Human Erythropoietin for Neuroprotection in Very Preterm Infants.
暂无分享，去创建一个
L. Held | J. Fauchère | C. Rüegger | B. Koller | G. Natalucci | B. Latal | Beate Sick
[1] Phuong T. Vu,et al. A Randomized Trial of Erythropoietin for Neuroprotection in Preterm Infants. , 2020, The New England journal of medicine.
[2] A. Ohlsson,et al. Early erythropoiesis-stimulating agents in preterm or low birth weight infants. , 2017, The Cochrane database of systematic reviews.
[3] H. Fischer,et al. Prophylactic Early Erythropoietin for Neuroprotection in Preterm Infants: A Meta-analysis , 2017, Pediatrics.
[4] L. Held,et al. Effect of Early Prophylactic High-Dose Recombinant Human Erythropoietin in Very Preterm Infants on Neurodevelopmental Outcome at 2 Years: A Randomized Clinical Trial. , 2016, JAMA.
[5] Daniel C. Cannon,et al. Preschool Assessment of Preterm Infants Treated With Darbepoetin and Erythropoietin , 2016, Pediatrics.
[6] J. Fauchère,et al. Safety of Early High-Dose Recombinant Erythropoietin for Neuroprotection in Very Preterm Infants. , 2015, The Journal of pediatrics.